INTRODUCTION
The high price of medicines and increasing expenditure on pharmaceuticals is a serious concern for governments in low-income countries where already over half of the population lacks regular access to essential medicines [1] . Currently, pharmaceuticals in low-income countries consume 30-60 percent of the recurrent healthcare budgets, yet the unmet need for medicines has been strongly associated with insufficient public spending on pharmaceuticals [2] . Poor families mostly rely upon public healthcare systems, where shortages of drugs are rampant [3] . In this situation the use of pharmacoeconomic principles is inevitable when an objective is to ensure that the limited resources are efficiently spent on drug therapies with large potentials to improve health. While developing countries commonly use National Essential Medicine Lists to prioritize the allocation of scarce public funds between drug therapies, little is known about the role of pharmacoeconomics in such decisions. In this editorial we therefore examine how pharmacoeconomics has influenced prioritization decisions between drugs in developing countries.
WHAT IS PHARMACOECONOMICS?
Pharmacoeconomic analysis involves the identification, measurement, valuation and comparison of costs and outcomes of alternative drug therapies. The underlying aim is to maximize treatment outcomes within limited budgets [4] . Due to the high alternative costs of scarce funds, it may be argued that pharmacoeconomics is relatively more important in developing countries than in developed countries. By alternative costs in this context we mean the health losses from making sub-optimal decisions.
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THE WAY FORWARD
Developing countries have limited financial resources to address the high burden of communicable and non-communicable diseases. As a consequence, policy makers and politicians are looking for politically acceptable solutions to bridge the gap between available resources and existing healthcare needs. We argue that pharmacoeconomics is one such solution to increase efficiency in resource allocation to drug therapies. Reference pricing and the use of generics has been advocated by a number of scholars as cost containment mechanisms [10, 17] . We concur with this focus, but argue that in addition, it is important to take into account the potential of pharmacoeconomic analyses to maximize the health benefits of the limited resources available. Reference pricing, use of generics and pharmacoeconomic analyses have complementary roles as cost containment and efficiency seeking strategies. Pharmacoeconomics is also needed for reimbursement purposes for the health insurance industry, which is growing rapidly in many developing countries. It is possible to increase the application of pharmacoeconomics in developing countries, despite the existing challenges. In a number of countries the seeds of pharmacoeconomics have been sown. But much remains to be done to facilitate expansion of the field through training, advocacy and legislation. For example, in 2000 the government of Tanzania successfully employed pharmacoeconomic analysis to inform the change of policy from chloroquine to sulphadoxine-pyrimethamine as first-choice drug for the management of uncomplicated malaria [18] . We see no substantial reasons why pharmacoeconomic principles should not be gradually introduced at different levels of the healthcare system. There are several steps that can be taken to improve the conduct of more pharmacoeconomics studies and increase their utilization in decision-making in developing countries: -first, more should be done to accelerate the introduction of pharmacoeconomics and health economics in training curriculums for medical and health science schools. At the same time, short courses and seminars should also be offered to practicing healthcare professionals; -second, efforts should be made to improve the availability of high-quality evidence to inform decision-making and to ensure that such evidence and the processes are also transparent; -third, given that pharmacoeconomic studies are relatively expensive and time consuming to conduct, policy makers and health planners should be ready to invest the necessary resources in order to make informed policy decisions; -fourth, healthcare authorities in developing countries have not done enough to ensure systematic use of economic evaluation in drug selection. It is now time to put in place legislation and policies that encourage the application of pharmacoeconomic principles in drug selection.
At the same time, we realize that health systems may also wish to consider other criteria than efficiency when setting healthcare priorities. Other arguments, such as severity of disease and patients' ability to benefit from the treatment, may be considered separately.
CONCLUSION
The field of pharmacoeconomics is in its infancy in most developing countries and has therefore had little influence on medicine selection for treatment guidelines and National Essential Medicine Lists. Despite some challenges, we believe it is time to increase the use of pharmacoeconomic analyses in developing countries through better training, advocacy and legislation.
